Mylan Inc. Credit Rating

Resultados 1 - 50 de 90

Página de 2 Next

Filtrar por:

Fecha	Tipo de Reporte	Título	Fuente
05 Oct 2023	Rating Action	Moody's affirms Viatris' Baa3 rating; outlook remains stable	Moody's Investors Service
27 Jul 2023	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
07 Nov 2022	Announcement	Moody's: Viatris strategic initiatives support credit profile but have execution risk	Moody's Investors Service
04 Oct 2022	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
10 Nov 2021	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Viatris Inc.	Moody's Investors Service
22 Feb 2021	Announcement	Moody's: Headwinds including COVID reduce Viatris' ability to weather potential future setbacks - a credit negative	Moody's Investors Service
22 Feb 2021	Issuer Comment	Viatris Inc.: Headwinds including COVID reduce Viatris' ability to weather potential future setbacks - a credit negative	Moody's Investors Service
15 Dec 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Viatris Inc.	Moody's Investors Service
14 Dec 2020	Rating Action	Moody's assigns Prime-3 short-term rating to Viatris' commercial paper program	Moody's Investors Service
15 Jun 2020	Announcement	Moody's: Upcoming debt financing brings Mylan/Upjohn one step closer to Viatris creation	Moody's Investors Service
14 Jan 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Mylan N.V.	Moody's Investors Service
30 Jul 2019	Issuer In-Depth	Mylan N.V.: Merger with Pfizer's Upjohn is credit positive but will present longer-term challenges for growth	Moody's Investors Service
29 Jul 2019	Rating Action	Moody's affirms Mylan's Baa3 ratings; outlook stable	Moody's Investors Service
01 Mar 2019	Rating Action	Moody's affirms Mylan's ratings; stable outlook	Moody's Investors Service
15 Feb 2019	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Mylan N.V.	Moody's Investors Service
31 Jan 2019	Issuer Comment	Mylan N.V.: Approval of generic version of Advair is credit positive for Mylan	Moody's Investors Service
31 Jul 2018	Rating Action	Moody's assigns Prime-3 rating to Mylan Inc.'s new CP program	Moody's Investors Service
16 May 2018	Rating Action	Moody's assigns Baa3 to Mylan's Euro offering	Moody's Investors Service
28 Mar 2018	Rating Action	Moody's assigns Baa3 to Mylan's offering	Moody's Investors Service
23 Jan 2018	Announcement	Moody's: European generic drug market growth to continue into 2020 on patent expiries, rising usage	Moody's Investors Service
09 Jun 2017	Rating Action	Moody's assigns Prime-3 rating to Mylan's new CP program	Moody's Investors Service
10 Oct 2016	Announcement	Moody's: Mylan's EpiPen settlement is credit negative; ratings unaffected	Moody's Investors Service
10 Oct 2016	Issuer Comment	Mylan N.V.: EpiPen settlement is credit negative; ratings unaffected	Moody's Investors Service
15 Feb 2016	Issuer Comment	Mylan's Deal for Meda Is Credit Negative	Moody's Investors Service
11 Feb 2016	Rating Action	Moody's affirms Mylan's Baa3; outlook stable	Moody's Investors Service
04 Dec 2015	Rating Action	Moody's assigns Baa3 to Mylan's notes offering	Moody's Investors Service
19 Nov 2015	Issuer Comment	Mylan Ends Hostile Pursuit of Perrigo, a Credit Positive for Both	Moody's Investors Service
18 Nov 2015	Credit Opinion	Mylan Inc.	Moody's Investors Service
13 Nov 2015	Rating Action	Moody's affirms Mylan's Baa3 rating; revises outlook to stable	Moody's Investors Service
14 Aug 2015	Announcement	Moody's: Mylan's Lowered Acceptance Condition on Perrigo Offer Is Credit Negative	Moody's Investors Service
14 Aug 2015	Issuer Comment	Mylan NV/Global Pharmaceuticals: Mylan’s Lowered Acceptance Condition on Perrigo Offer Is Credit Negative	Moody's Investors Service
31 Jul 2015	Rating Action	Moody's Affirms Mylan's Baa3; outlook changed to negative from developing	Moody's Investors Service
27 Apr 2015	Issuer Comment	Teva's Bid for Mylan Would Significantly Increase Its Leverage	Moody's Investors Service
24 Apr 2015	Announcement	Moody's: Mylan's Offer for Perrigo Credit Negative but Could be Investment Grade	Moody's Investors Service
24 Apr 2015	Issuer Comment	Mylan NV/Global Pharmaceuticals: Mylan's Offer for Perrigo Credit Negative but Could Be Investment Grade
21 Apr 2015	Rating Action	Moody's Affirms Mylan's Baa3; outlook changed to developing	Moody's Investors Service
09 Apr 2015	Announcement	Moody's: Mylan/Perrigo Combination Would Enhance Scale and Diversity But Many Unknowns Remain	Moody's Investors Service
09 Apr 2015	Issuer Comment	Mylan NV: Mylan/Perrigo Combination Would Enhance Scale and Diversity But Many Unknowns Remain	Moody's Investors Service
25 Aug 2014	Announcement	Moody's: Indian pharmaceutical sector to see strong growth	Moody's Investors Service
17 Jul 2014	Issuer Comment	Mylan's All-Stock Acquisition of Abbott Products Is Credit Positive	Moody's Investors Service
14 Jul 2014	Announcement	Moody's: All-stock acquisition of mature products from Abbott is credit positive for Mylan	Moody's Investors Service
14 Jul 2014	Issuer Comment	Moody's: All-stock acquisition of mature products from Abbott is credit positive for Mylan	Moody's Investors Service
03 Apr 2014	Issuer Comment	US Supreme Court's Hearing of Copaxone Case Is Positive for Teva	Moody's Investors Service
07 Mar 2014	Announcement	Moody's Says Mylan's New 5-Year Management Incentive Plan is Credit Negative	Moody's Investors Service
07 Mar 2014	Issuer Comment	Moody's Says Mylan's New 5-Year Management Incentive Plan is Credit Negative	Moody's Investors Service
20 Nov 2013	Credit Focus	Teva: Copaxone Threat Puts A3 Rating at Risk	Moody's Investors Service
19 Nov 2013	Rating Action	Moody's rates Mylan's notes offering Baa3	Moody's Investors Service
24 Jun 2013	Issuer Comment	US Supreme Court's Pay-for-Delay Ruling Is Credit Negative for Pharma Firms	Moody's Investors Service
18 Jun 2013	Announcement	Moody's: Supreme Court Ruling Increases Legal Risk and Uncertainty for Generic Pharma Firms	Moody's Investors Service
18 Jun 2013	Rating Action	Moody's rates Mylan's notes Baa3; stable outlook	Moody's Investors Service

Resultados 1 - 50 de 90

Página de 2 Next

Estudios & Calificaciones

Productos & Soluciones

Noticias & Eventos

Usuarios Registrados

¿No se ha registrado?

Moody's Integrity Hotline

Via the Internet:

By telephone from the United States:

By telephone from outside the United States: